Hepatitis B is a contagious disease that is in the spotlight for worldwide eradication.
Heplisav has been deemed safe in 3 pivotal Phase III trials. Its superior efficacy is not even in question.
The vaccine’s risk benefit profile makes it very hard for the FDA to reject it the second time round.
DVAX is at an all-time low and represents a golden opportunity for a multi-bagger.